Molecular Point of Care (mPOC) Devices Market Size, Share and Growth Outlook 2026: By Product (Assays and Kits, Instruments and Analyzers, Software and Services), By Technology, By Application, By End-User, By Sample Type, Companies to 2034.
The global Molecular Point of Care (mPOC) Devices Market size is forecast to increase from $2.3 Billion in 2026 to $5 Billion in 2034 at a CAGR of 10.2% between 2026 and 2034.
The Molecular Point of Care Devices market report provides detailed analysis and outlook of Molecular Point of Care Devices segments including By Product (Assays and Kits, Instruments and Analyzers, Software and Services), By Technology (Real-Time Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification (INAAT), Other Technologies), By Application (Respiratory Diseases, Sexually Transmitted Diseases, Hospital-Acquired Infections, Cancer, Hepatitis, Gastrointestinal Disorders, Other Applications), By End-User (Hospitals and Intensive Care Units, Physicians' Offices and Clinics, Research Institutes, Other End-Users), By Sample Type (Blood Samples, Urine Samples, Other Sample Types) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Molecular Point of Care (mPOC) Devices Industry Overview
Rapid Decentralized Diagnostics Driving Molecular Point-of-Care Adoption
The molecular point of care devices industry is experiencing strong growth as healthcare providers increasingly seek rapid, laboratory-quality diagnostic results directly at the patient care site. Molecular point-of-care systems are transforming infectious disease testing, respiratory diagnostics, gastrointestinal pathogen detection, and emergency care workflows by eliminating the delays associated with centralized laboratory processing. Advances in polymerase chain reaction technology, cartridge-based testing, automation, and regulatory approvals are enabling healthcare facilities to deliver highly accurate molecular results within minutes. The industry is benefiting from growing demand for decentralized diagnostics across hospitals, urgent care centers, physician offices, pharmacies, and community healthcare settings, where rapid clinical decision-making is essential for improving patient outcomes and optimizing treatment pathways.
Regulatory Approvals Accelerating Market Expansion
A defining industry trend is the growing number of regulatory clearances and waivers that allow molecular diagnostics to move beyond traditional laboratory environments. bioM?rieux strengthened this transition through CE marking under the In Vitro Diagnostic Regulation for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus Panel and its corresponding Mini version, validating their use in near-patient testing environments. DiaSorin further expanded the market through FDA 510(k) clearance and CLIA waiver approval for the LIAISON NES platform, which delivers laboratory-grade PCR results within approximately 15 minutes. To support commercial deployment, the company established an exclusive U.S. hospital distribution agreement with Fisher Scientific. These developments highlight the industry's focus on bringing highly accurate molecular testing capabilities directly to frontline healthcare settings while maintaining regulatory compliance and diagnostic reliability.
Ultra-Fast PCR and Pandemic Preparedness Strengthening Industry Development
Manufacturers are increasingly prioritizing ultra-fast molecular testing platforms capable of supporting decentralized healthcare delivery and public health preparedness initiatives. LEX Diagnostics advanced this segment through FDA clearance and CLIA waiver authorization for its VELO molecular point-of-care platform, which demonstrated strong performance across multiple respiratory pathogens during extensive evaluation in CLIA-waived settings. At the same time, Cepheid expanded its molecular diagnostics portfolio through CE marking for the Xpert® GI Panel under IVDR, strengthening its presence in gastrointestinal pathogen detection. The company's selection as a collaborator by the U.S. Centers for Disease Control and Prevention further highlights the growing role of molecular point-of-care technologies in national pandemic preparedness strategies. These developments reflect a broader industry movement toward highly accessible, rapid, and clinically actionable molecular diagnostics that support both routine healthcare delivery and emerging infectious disease response efforts.
Molecular Point of Care Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Molecular Point of Care Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Roche Diagnostics, Danaher Corporation (Cepheid), bioM?rieux, Hologic, Inc., Thermo Fisher Scientific, QIAGEN N.V., QuidelOrtho Corporation, Becton, Dickinson and Company, LumiraDx. The Molecular Point of Care Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Molecular Point of Care Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Molecular Point of Care Devices industry include- Abbott Laboratories, Roche Diagnostics, Danaher Corporation (Cepheid), bioM?rieux, Hologic, Inc., Thermo Fisher Scientific, QIAGEN N.V., QuidelOrtho Corporation, Becton, Dickinson and Company, LumiraDx. The Molecular Point of Care Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Molecular Point of Care Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Molecular Point of Care Devices market remains one of the strongest-performing segments in the country.
The US Molecular Point of Care Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Molecular Point of Care Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Molecular Point of Care Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Molecular Point of Care Devices markets
Canada's strong Molecular Point of Care Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Molecular Point of Care Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Molecular Point of Care Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Molecular Point of Care Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Molecular Point of Care Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Molecular Point of Care Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Molecular Point of Care Devices market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Molecular Point of Care Devices sales through 2034
France Molecular Point of Care Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Molecular Point of Care Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Molecular Point of Care Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Molecular Point of Care Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Molecular Point of Care Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Molecular Point of Care Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Molecular Point of Care Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Molecular Point of Care Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Molecular Point of Care Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Molecular Point of Care Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Molecular Point of Care Devices Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Molecular Point of Care Devices Market Segmentation
By Product
Assays and Kits
Instruments and Analyzers
Software and Services
By Technology
Real-Time Polymerase Chain Reaction (RT-PCR)
Isothermal Nucleic Acid Amplification (INAAT)
Other Technologies
By Application
Respiratory Diseases
Sexually Transmitted Diseases
Hospital-Acquired Infections
Cancer
Hepatitis
Gastrointestinal Disorders
Other Applications
By End-User
Hospitals and Intensive Care Units
Physicians' Offices and Clinics
Research Institutes
Other End-Users
By Sample Type
Blood Samples
Urine Samples
Other Sample Types
Leading Companies in Molecular Point of Care Devices Industry (2026)
Abbott Laboratories
Roche Diagnostics
Danaher Corporation (Cepheid)
bioM?rieux
Hologic, Inc.
Thermo Fisher Scientific
QIAGEN N.V.
QuidelOrtho Corporation
Becton, Dickinson and Company
LumiraDx
Countries Included
The Molecular Point of Care Devices market report provides detailed analysis and outlook of Molecular Point of Care Devices segments including By Product (Assays and Kits, Instruments and Analyzers, Software and Services), By Technology (Real-Time Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification (INAAT), Other Technologies), By Application (Respiratory Diseases, Sexually Transmitted Diseases, Hospital-Acquired Infections, Cancer, Hepatitis, Gastrointestinal Disorders, Other Applications), By End-User (Hospitals and Intensive Care Units, Physicians' Offices and Clinics, Research Institutes, Other End-Users), By Sample Type (Blood Samples, Urine Samples, Other Sample Types) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Molecular Point of Care (mPOC) Devices Industry Overview
Rapid Decentralized Diagnostics Driving Molecular Point-of-Care Adoption
The molecular point of care devices industry is experiencing strong growth as healthcare providers increasingly seek rapid, laboratory-quality diagnostic results directly at the patient care site. Molecular point-of-care systems are transforming infectious disease testing, respiratory diagnostics, gastrointestinal pathogen detection, and emergency care workflows by eliminating the delays associated with centralized laboratory processing. Advances in polymerase chain reaction technology, cartridge-based testing, automation, and regulatory approvals are enabling healthcare facilities to deliver highly accurate molecular results within minutes. The industry is benefiting from growing demand for decentralized diagnostics across hospitals, urgent care centers, physician offices, pharmacies, and community healthcare settings, where rapid clinical decision-making is essential for improving patient outcomes and optimizing treatment pathways.
Regulatory Approvals Accelerating Market Expansion
A defining industry trend is the growing number of regulatory clearances and waivers that allow molecular diagnostics to move beyond traditional laboratory environments. bioM?rieux strengthened this transition through CE marking under the In Vitro Diagnostic Regulation for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus Panel and its corresponding Mini version, validating their use in near-patient testing environments. DiaSorin further expanded the market through FDA 510(k) clearance and CLIA waiver approval for the LIAISON NES platform, which delivers laboratory-grade PCR results within approximately 15 minutes. To support commercial deployment, the company established an exclusive U.S. hospital distribution agreement with Fisher Scientific. These developments highlight the industry's focus on bringing highly accurate molecular testing capabilities directly to frontline healthcare settings while maintaining regulatory compliance and diagnostic reliability.
Ultra-Fast PCR and Pandemic Preparedness Strengthening Industry Development
Manufacturers are increasingly prioritizing ultra-fast molecular testing platforms capable of supporting decentralized healthcare delivery and public health preparedness initiatives. LEX Diagnostics advanced this segment through FDA clearance and CLIA waiver authorization for its VELO molecular point-of-care platform, which demonstrated strong performance across multiple respiratory pathogens during extensive evaluation in CLIA-waived settings. At the same time, Cepheid expanded its molecular diagnostics portfolio through CE marking for the Xpert® GI Panel under IVDR, strengthening its presence in gastrointestinal pathogen detection. The company's selection as a collaborator by the U.S. Centers for Disease Control and Prevention further highlights the growing role of molecular point-of-care technologies in national pandemic preparedness strategies. These developments reflect a broader industry movement toward highly accessible, rapid, and clinically actionable molecular diagnostics that support both routine healthcare delivery and emerging infectious disease response efforts.
Molecular Point of Care Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Molecular Point of Care Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Roche Diagnostics, Danaher Corporation (Cepheid), bioM?rieux, Hologic, Inc., Thermo Fisher Scientific, QIAGEN N.V., QuidelOrtho Corporation, Becton, Dickinson and Company, LumiraDx. The Molecular Point of Care Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Molecular Point of Care Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Molecular Point of Care Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Molecular Point of Care Devices companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Molecular Point of Care Devices markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Molecular Point of Care Devices industry include- Abbott Laboratories, Roche Diagnostics, Danaher Corporation (Cepheid), bioM?rieux, Hologic, Inc., Thermo Fisher Scientific, QIAGEN N.V., QuidelOrtho Corporation, Becton, Dickinson and Company, LumiraDx. The Molecular Point of Care Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Molecular Point of Care Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Molecular Point of Care Devices market remains one of the strongest-performing segments in the country.
The US Molecular Point of Care Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Molecular Point of Care Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Molecular Point of Care Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Molecular Point of Care Devices markets
Canada's strong Molecular Point of Care Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Molecular Point of Care Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Molecular Point of Care Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Molecular Point of Care Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Molecular Point of Care Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Molecular Point of Care Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Molecular Point of Care Devices market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Molecular Point of Care Devices sales through 2034
France Molecular Point of Care Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Molecular Point of Care Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Molecular Point of Care Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Molecular Point of Care Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Molecular Point of Care Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Molecular Point of Care Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Molecular Point of Care Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Molecular Point of Care Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Molecular Point of Care Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Molecular Point of Care Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Molecular Point of Care Devices Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Molecular Point of Care Devices Market Segmentation
By Product
Assays and Kits
Instruments and Analyzers
Software and Services
By Technology
Real-Time Polymerase Chain Reaction (RT-PCR)
Isothermal Nucleic Acid Amplification (INAAT)
Other Technologies
By Application
Respiratory Diseases
Sexually Transmitted Diseases
Hospital-Acquired Infections
Cancer
Hepatitis
Gastrointestinal Disorders
Other Applications
By End-User
Hospitals and Intensive Care Units
Physicians' Offices and Clinics
Research Institutes
Other End-Users
By Sample Type
Blood Samples
Urine Samples
Other Sample Types
Leading Companies in Molecular Point of Care Devices Industry (2026)
Abbott Laboratories
Roche Diagnostics
Danaher Corporation (Cepheid)
bioM?rieux
Hologic, Inc.
Thermo Fisher Scientific
QIAGEN N.V.
QuidelOrtho Corporation
Becton, Dickinson and Company
LumiraDx
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Molecular Point of Care Devices Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Molecular Point of Care Devices Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL MOLECULAR POINT OF CARE DEVICES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Molecular Point of Care Devices Markets in 2026
3.2. Global Historic and Forecast Molecular Point of Care Devices Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Molecular Point of Care Devices Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Molecular Point of Care Devices Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Molecular Point of Care Devices Value Chain
CHAPTER 4- MOLECULAR POINT OF CARE DEVICES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Molecular Point of Care Devices Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- MOLECULAR POINT OF CARE DEVICES MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product
Assays and Kits
Instruments and Analyzers
Software and Services
By Technology
Real-Time Polymerase Chain Reaction (RT-PCR)
Isothermal Nucleic Acid Amplification (INAAT)
Other Technologies
By Application
Respiratory Diseases
Sexually Transmitted Diseases
Hospital-Acquired Infections
Cancer
Hepatitis
Gastrointestinal Disorders
Other Applications
By End-User
Hospitals and Intensive Care Units
Physicians' Offices and Clinics
Research Institutes
Other End-Users
By Sample Type
Blood Samples
Urine Samples
Other Sample Types
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Molecular Point of Care Devices Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
7.5. North America Molecular Point of Care Devices Market Size Outlook by Type
7.6. North America Molecular Point of Care Devices Market Size Outlook by Application
7.7. North America Molecular Point of Care Devices Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Molecular Point of Care Devices Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Molecular Point of Care Devices Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Molecular Point of Care Devices Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Molecular Point of Care Devices Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Molecular Point of Care Devices Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Molecular Point of Care Devices Companies
CHAPTER 8- EUROPE MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Molecular Point of Care Devices Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
8.5. Europe Molecular Point of Care Devices Market Size Outlook by Type
8.6. Europe Molecular Point of Care Devices Market Size Outlook by Application
8.7. Europe Molecular Point of Care Devices Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Molecular Point of Care Devices Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Molecular Point of Care Devices Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Molecular Point of Care Devices Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Molecular Point of Care Devices Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Molecular Point of Care Devices Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Molecular Point of Care Devices Companies
CHAPTER 9- ASIA PACIFIC MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Molecular Point of Care Devices Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Molecular Point of Care Devices Market Size Outlook by Type
9.6. Asia Pacific Molecular Point of Care Devices Market Size Outlook by Application
9.7. Asia Pacific Molecular Point of Care Devices Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Molecular Point of Care Devices Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Molecular Point of Care Devices Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Molecular Point of Care Devices Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Molecular Point of Care Devices Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Molecular Point of Care Devices Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Molecular Point of Care Devices Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Molecular Point of Care Devices Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
10.5. South and Central America Molecular Point of Care Devices Market Size Outlook by Type
10.6. South and Central America Molecular Point of Care Devices Market Size Outlook by Application
10.7. South and Central America Molecular Point of Care Devices Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Molecular Point of Care Devices Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Molecular Point of Care Devices Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Molecular Point of Care Devices Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Molecular Point of Care Devices Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Molecular Point of Care Devices Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Molecular Point of Care Devices Companies
CHAPTER 11- MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Molecular Point of Care Devices Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Molecular Point of Care Devices Market Size Outlook by Type
11.6. Middle East and Africa Molecular Point of Care Devices Market Size Outlook by Application
11.7. Middle East and Africa Molecular Point of Care Devices Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Molecular Point of Care Devices Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Molecular Point of Care Devices Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Molecular Point of Care Devices Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Molecular Point of Care Devices Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Molecular Point of Care Devices Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Molecular Point of Care Devices Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Molecular Point of Care Devices Industry
Abbott Laboratories
Roche Diagnostics
Danaher Corporation (Cepheid)
bioM?rieux
Hologic, Inc.
Thermo Fisher Scientific
QIAGEN N.V.
QuidelOrtho Corporation
Becton, Dickinson and Company
LumiraDx
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Molecular Point of Care Devices Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Molecular Point of Care Devices Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL MOLECULAR POINT OF CARE DEVICES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Molecular Point of Care Devices Markets in 2026
3.2. Global Historic and Forecast Molecular Point of Care Devices Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Molecular Point of Care Devices Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Molecular Point of Care Devices Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Molecular Point of Care Devices Value Chain
CHAPTER 4- MOLECULAR POINT OF CARE DEVICES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Molecular Point of Care Devices Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- MOLECULAR POINT OF CARE DEVICES MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product
Assays and Kits
Instruments and Analyzers
Software and Services
By Technology
Real-Time Polymerase Chain Reaction (RT-PCR)
Isothermal Nucleic Acid Amplification (INAAT)
Other Technologies
By Application
Respiratory Diseases
Sexually Transmitted Diseases
Hospital-Acquired Infections
Cancer
Hepatitis
Gastrointestinal Disorders
Other Applications
By End-User
Hospitals and Intensive Care Units
Physicians' Offices and Clinics
Research Institutes
Other End-Users
By Sample Type
Blood Samples
Urine Samples
Other Sample Types
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Molecular Point of Care Devices Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
7.5. North America Molecular Point of Care Devices Market Size Outlook by Type
7.6. North America Molecular Point of Care Devices Market Size Outlook by Application
7.7. North America Molecular Point of Care Devices Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Molecular Point of Care Devices Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Molecular Point of Care Devices Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Molecular Point of Care Devices Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Molecular Point of Care Devices Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Molecular Point of Care Devices Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Molecular Point of Care Devices Companies
CHAPTER 8- EUROPE MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Molecular Point of Care Devices Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
8.5. Europe Molecular Point of Care Devices Market Size Outlook by Type
8.6. Europe Molecular Point of Care Devices Market Size Outlook by Application
8.7. Europe Molecular Point of Care Devices Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Molecular Point of Care Devices Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Molecular Point of Care Devices Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Molecular Point of Care Devices Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Molecular Point of Care Devices Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Molecular Point of Care Devices Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Molecular Point of Care Devices Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Molecular Point of Care Devices Companies
CHAPTER 9- ASIA PACIFIC MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Molecular Point of Care Devices Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Molecular Point of Care Devices Market Size Outlook by Type
9.6. Asia Pacific Molecular Point of Care Devices Market Size Outlook by Application
9.7. Asia Pacific Molecular Point of Care Devices Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Molecular Point of Care Devices Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Molecular Point of Care Devices Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Molecular Point of Care Devices Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Molecular Point of Care Devices Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Molecular Point of Care Devices Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Molecular Point of Care Devices Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Molecular Point of Care Devices Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Molecular Point of Care Devices Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
10.5. South and Central America Molecular Point of Care Devices Market Size Outlook by Type
10.6. South and Central America Molecular Point of Care Devices Market Size Outlook by Application
10.7. South and Central America Molecular Point of Care Devices Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Molecular Point of Care Devices Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Molecular Point of Care Devices Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Molecular Point of Care Devices Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Molecular Point of Care Devices Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Molecular Point of Care Devices Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Molecular Point of Care Devices Companies
CHAPTER 11- MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DEVICES MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Molecular Point of Care Devices Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Molecular Point of Care Devices Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Molecular Point of Care Devices Market Size Outlook by Type
11.6. Middle East and Africa Molecular Point of Care Devices Market Size Outlook by Application
11.7. Middle East and Africa Molecular Point of Care Devices Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Molecular Point of Care Devices Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Molecular Point of Care Devices Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Molecular Point of Care Devices Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Molecular Point of Care Devices Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Molecular Point of Care Devices Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Molecular Point of Care Devices Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Molecular Point of Care Devices Industry
Abbott Laboratories
Roche Diagnostics
Danaher Corporation (Cepheid)
bioM?rieux
Hologic, Inc.
Thermo Fisher Scientific
QIAGEN N.V.
QuidelOrtho Corporation
Becton, Dickinson and Company
LumiraDx
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
